查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1992953

癌症生技药品市场：2026-2032年全球市场预测（依产品类型、癌症类型、最终用户和通路划分）

Cancer Biologics Market by Product Type, Cancer Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年癌症生技药品市值为1,088.8亿美元，预计到2026年将成长至1,165.8亿美元，复合年增长率为6.59%，到2032年将达到1,703亿美元。

主要市场统计数据
基准年 2025 1088.8亿美元
预计年份：2026年 1165.8亿美元
预测年份 2032 1703亿美元
复合年增长率 (%) 6.59%

癌症生物製剂领域中影响策略决策的科学进步、监管复杂性和商业性需求的关键背景资讯。

癌症生物製剂领域正处于一个十字路口，科学突破、不断演变的法规结构和商业模式在此交汇融合。免疫肿瘤学、细胞和基因疗法以及精准标靶生技药品的最新进展，在拓展治疗可能性的同时，也增加了计画的复杂性。因此，产品开发路径如今需要更深入的转化证据、更具适应性的临床试验设计，以及监管、生产和商业部门之间的早期协作。本文旨在建构一个将临床创新与实际商业需求结合的整合管理观点。

重新定义癌症生技药品的发展路径和策略挑战：技术、商业和医疗保健服务的关键变革的融合。

生技药品领域正经历着一场变革性的转型，其驱动力包括技术成熟、资金筹措模式的转变以及患者期望的不断提高。在技​​术层面，细胞疗法和基因编辑技术正从概念验证（PoC）阶段迈向迭代优化阶段，优先考虑安全性、可生产性和持续疗效。同时，儘管双特异性抗体和抗体药物复合体（ADC）正在拓展治疗的边界，但单株抗体仍然是标靶治疗的基石。这些治疗方法的转变促使申办方重新评估其研发时间表，并投资于支援快速迭代开发的平台能力。

2025 年美国关税调整对采购、製造、物流和长期商业化规划的策略影响。

2025年宣布的关税政策调整的累积影响，正在美国进口和出口的生技药品的采购、生产和分销的各个环节带来新的变数。关税调整可能会改变原料、组件和成品生技药品生产地点的判定标准，促使企业重新审视其供应商组合，并对关键投入品实施双重采购以降低风险。同时，不断上涨的进口成本也凸显了本地生产投资以及与国内合约研发生产力机构（CDMO）建立策略伙伴关係的重要性，以维持供应链的连续性和成本的可预测性。

将治疗方法、癌症适应症、终端用户趋势和分销管道与业务运营和商业策略联繫起来的基于详细细分的洞察。

按细分市场了解癌症生技药品市场，有助于揭示科学机会、商业性可行性和营运复杂性之间的交汇点。按产品类型划分，该市场涵盖癌症疫苗、细胞疗法、基因疗法、单株抗体和重组蛋白。在单株抗体领域，抗CD20、抗HER2、抗PD-1/PD-L1和抗VEGF等成熟类别持续影响临床策略，而Obinutuzumab、利妥昔单抗、Rituximab、曲Pertuzumab珠单抗、阿特珠单抗、纳AtezolizumabNivolumab和Bevacizumab等个别药物定位和生命週期的抗定位。这种详细的产品层面分析突显了在生产复杂性、低温运输物流和监管证据方面的不同需求。

区域间在临床能力、法规结构和生产能力的差异，会影响市场进入和商业化策略。

区域趋势对癌症生技药品的整体研发策略、监管合作和商业化路径有显着影响。在美洲，先进的临床生态系统、以支付主导的证据要求以及完善的生产基础设施，既带来了机会，也带来了挑战。在该地区运作的相关人员必须平衡强有力的临床证据的获取、与支付方的沟通以及供应链的柔软性。在欧洲、中东和非洲（EMEA），不同的法规环境和报销框架要求企业采取因地制宜的市场进入策略和区域性定价策略。与区域分销商建立策略伙伴关係关係对于应对报销和监管方面的细微差异至关重要。

主要企业如何重组其研发、製造和商业职能部门的能力，以保持创新并缩短产品上市时间。

肿瘤生物製剂领域的主要企业正透过对平台技术的策略性投资、扩大生产能力以及建立协作生态系统来应对日益复杂的挑战。许多机构正在采用整合开发模式，儘早将临床、监管和生产方面的相关人员聚集在一起，从而降低规模化生产的风险并加快跨职能决策。策略联盟、授权和定向收购是获取细胞疗法生产、基因载体生产和生物标记主导开发所需先进分析能力的常用手段。

制定可操作的策略重点，以协调临床创新、生产韧性、支付方参与和通路特定商业化，实现永续成长。

产业领导者应优先考虑如何使科学研究机会与商业可行性及支付方预期相契合。首先，从早期专案阶段就将临床开发与可扩展的生产方案结合，可以减少后续环节的延误，并加速向商业化供应的过渡。企业应考虑采用模组化和分散式生产方式，作为风险分散型生产策略的一部分，以减少供应链中的单点故障。其次，早期投资于真实世界数据（REW）的生成和卫生经济学能力建设，将有助于加强与支付方的沟通，并促进建立更可预测的准入途径。

结合与关键相关人员的对话、可靠的二手资料和情境分析的调查方法，确保了可靠且可操作的见解。

本研究采用系统性的调查方法，整合一手与二手讯息，旨在兼顾深入洞察与实际应用。一手资讯包括对临床负责人、生产专家、支付方和分销合作伙伴的结构化访谈，以及匿名化的医疗专业人员问卷调查，以了解实际挑战和新兴实践。二手资讯包括同行评审文献、监管指南、临床试验註册数据和上市公司文件，以检验趋势并根据临床和商业性管道对产品原型进行分类。

结论整合了科学潜力、实际情况以及将创新转化为可持续的临床和商业性成功所需的策略行动。

总之，癌症生技药品已进入一个阶段，在这个阶段，科学潜力必须与严谨的运作和战略远见结合。儘管细胞疗法和基因疗法等突破性治疗方法，以及单株抗体製剂的不断发展，正在创造广泛的治疗可能性，但要成功地将这些疗法转化为对患者的益处，整合开发、生产和商业化流程至关重要。那些积极开展跨职能团队合作、投资稳健的供应链并建立以支付观点的循证策略的机构，最有能力将科学进步转化为可持续的临床和商业性成功。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 癌症生技药品市场：依产品类型划分

  • 癌症疫苗
  • 细胞疗法
  • 基因治疗
  • 单株抗体
    • 抗CD20
      • Obinutuzumab
      • Rituximab
    • 抗HER2
      • Pertuzumab
      • 曲妥珠单抗
    • 抗PD-1/PD-L1
      • Atezolizumab
      • Nivolumab
      • Pembrolizumab
    • 抗 VEGF
  • 重组蛋白

第九章：以癌症类型分類的癌症生技药品市场

  • 乳癌
  • 结肠癌
  • 骨髓恶性肿瘤
  • 肺癌
  • 恶性黑色素瘤
  • 摄护腺癌

第十章 癌症生技药品市场：依最终用户划分

  • 门诊手术中心
  • 居家医疗设施
  • 医院和诊所
  • 肿瘤中心

第十一章 癌症生技药品市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章生技药品市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 癌症生技药品市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章生技药品市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国癌症生技药品市场

第十六章：中国癌症生技药品市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • ADC Therapeutics SA
  • Agenus Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Autolus Therapeutics plc
  • BeiGene, Ltd.
  • Biocon Limited
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Modex Therapeutics AG
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Seagen Inc.
Product Code: MRR-1A1A064C014D

The Cancer Biologics Market was valued at USD 108.88 billion in 2025 and is projected to grow to USD 116.58 billion in 2026, with a CAGR of 6.59%, reaching USD 170.30 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 108.88 billion
Estimated Year [2026] USD 116.58 billion
Forecast Year [2032] USD 170.30 billion
CAGR (%) 6.59%

Essential contextual framing of scientific advances, regulatory complexity, and commercial imperatives shaping strategic decision-making in cancer biologics

The cancer biologics domain is at an inflection point where scientific breakthroughs converge with shifting regulatory frameworks and evolving commercial models. Recent advances in immuno-oncology, cell and gene modalities, and precision-targeted biologics have expanded therapeutic possibilities while simultaneously elevating program complexity. As a result, product development pathways now demand deeper translational evidence, adaptive clinical designs, and earlier alignment across regulatory, manufacturing, and commercial functions. This introduction sets the stage for an integrated executive view that ties clinical innovation to pragmatic business imperatives.

Throughout this document, stakeholders will find synthesized insights intended to support strategic planning, portfolio prioritization, and partnership decisions. The goal is to present a cohesive narrative that balances scientific potential with operational realities, helping leaders anticipate trade-offs between speed to clinic, scale-up risk, and payer engagement. By framing opportunities alongside common constraints, this introduction prepares decision-makers to interpret the subsequent sections with clarity and purpose.

Pivotal technological, commercial, and care-delivery transformations converging to redefine development pathways and strategic imperatives across cancer biologics

The landscape of cancer biologics is undergoing transformative shifts driven by technological maturation, shifting financing models, and evolving patient expectations. On the technological front, cell therapies and gene editing techniques are moving from proof-of-concept toward iterative optimization that prioritizes safety, manufacturability, and durability of response. At the same time, monoclonal antibodies remain a backbone of targeted therapy, even as bispecific formats and antibody-drug conjugates push therapeutic boundaries. These modality-driven changes are causing sponsors to re-evaluate R&D timelines and to invest in platform capabilities that support rapid iteration.

Commercially, payer scrutiny and value-based contracting are driving earlier evidence generation focused on real-world effectiveness and health economics. Partnerships between biopharma companies, contract manufacturers, and specialty service providers are also deepening to address capacity constraints and reduce time-to-treatment. Moreover, patient-centric care models, including home-based administration and decentralized trials, are reshaping distribution and delivery strategies. Together, these shifts require companies to be more agile in aligning clinical development with commercial and supply chain strategies, while maintaining a relentless focus on safety and evidence quality.

Strategic implications of United States tariff adjustments in 2025 on sourcing, manufacturing, logistics, and long-term commercialization planning

The cumulative effects of tariff policy changes announced for 2025 have introduced new variables across sourcing, manufacturing, and distribution for cancer biologics entering or leaving the United States. Tariff adjustments can alter the calculus for where raw materials, components, and finished biologics are manufactured, prompting companies to reassess supplier portfolios and dual-source critical inputs to reduce exposure. In parallel, increased import costs can raise the importance of localized manufacturing investments and strategic partnerships with domestic contract development and manufacturing organizations to preserve supply chain continuity and cost predictability.

Beyond near-term sourcing decisions, tariff dynamics influence long-range planning for capital investments, pricing strategies, and contractual terms with distributors and payers. Companies managing global clinical programs may face administrative burdens linked to customs classification and compliance, which can lengthen lead times and complicate logistics planning. Consequently, commercial teams must work closely with regulatory, legal, and procurement functions to model tariff scenarios, renegotiate supplier agreements where feasible, and prioritize modular manufacturing approaches that enable incremental capacity expansion without excessive fixed-cost commitments.

Deep segmentation-driven insights linking modality, cancer indication, end-user dynamics, and distribution channels to operational and commercial strategy

Segmented understanding of the cancer biologics market illuminates where scientific opportunity intersects with commercial viability and operational complexity. When considered by product type, the market spans cancer vaccines, cell therapy, gene therapy, monoclonal antibodies, and recombinant proteins; within monoclonal antibodies, established classes such as Anti-CD20, Anti-HER2, Anti-PD-1/PD-L1, and Anti-VEGF continue to shape clinical strategies, and individual agents like Obinutuzumab, Rituximab, Pertuzumab, Trastuzumab, Atezolizumab, Nivolumab, Pembrolizumab, and Bevacizumab serve as reference points for competitive positioning and lifecycle management. This product-level granularity highlights differing demands around manufacturing complexity, cold-chain logistics, and regulatory evidence.

When analyzed through the lens of cancer type, distinctions among breast cancer, colorectal cancer, hematological malignancies, lung cancer, melanoma, and prostate cancer clarify patient population dynamics and therapeutic endpoints, which in turn inform trial design and commercialization focus. End-user segmentation-spanning ambulatory surgery centers, homecare settings, hospitals and clinics, and specialized oncology centers-reveals varied administration pathways and reimbursement touchpoints, creating differentiated service and distribution models. Finally, distribution channel segmentation across hospital pharmacies, online pharmacies, retail pharmacies, and specialty distributors underscores the importance of channel-specific strategies for patient access, adherence support, and supply chain resilience, and it encourages targeted commercial models that reflect each channel's regulatory and operational realities.

Regional variations in clinical capacity, regulatory frameworks, and manufacturing capabilities that shape tailored market entry and commercialization strategies

Regional dynamics materially influence development strategies, regulatory interactions, and commercialization pathways across cancer biologics. In the Americas, a combination of advanced clinical ecosystems, payer-driven evidence requirements, and a strong manufacturing base creates both opportunity and complexity; stakeholders operating here must align robust clinical evidence generation with payer engagement and supply chain flexibility. Europe, Middle East & Africa present heterogeneous regulatory environments and reimbursement frameworks where adaptive market entry tactics and localized pricing strategies are essential, and strategic partnerships with regional distributors are often critical to navigate reimbursement and regulatory nuances.

Asia-Pacific markets exhibit a mix of large patient populations and rapidly expanding clinical trial capacity, accompanied by rising domestic capabilities in biologics manufacturing. Companies engaging in this region frequently balance accelerated enrollment advantages with the need for tailored evidence packages and supply chain adaptations to meet local regulatory expectations. Taken together, these regional vectors require nuanced approaches to clinical strategy, manufacturing footprint decisions, and commercialization planning that reflect both macroeconomic conditions and country-level regulatory idiosyncrasies.

How leading organizations are reshaping capabilities across R&D, manufacturing, and commercial functions to sustain innovation and improve time-to-market

Leading companies in the cancer biologics arena are responding to heightened complexity through strategic investments in platform technologies, expanded manufacturing capacity, and collaborative ecosystems. Many organizations are adopting integrated development models that bring clinical, regulatory, and manufacturing stakeholders together earlier to de-risk scale-up and accelerate cross-functional decision-making. Strategic alliances, licensing arrangements, and targeted acquisitions are common tools used to secure capabilities in cell therapy manufacturing, gene vector production, and advanced analytics for biomarker-driven development.

Operationally, firms are prioritizing supply chain resiliency by diversifying suppliers, qualifying alternate fill-finish partners, and investing in cold-chain infrastructure. On the commercial side, companies are expanding capabilities in real-world data generation and value demonstration to better position biologics with payers and health systems. Talent strategies are also evolving, with leaders recruiting cross-disciplinary teams capable of navigating regulatory complexity while optimizing manufacturing throughput and patient access initiatives. Collectively, these company-level moves indicate a shift toward more integrated, risk-aware operations that can sustain both innovation and commercialization at scale.

Actionable strategic priorities to align clinical innovation, manufacturing resilience, payer engagement, and channel-specific commercialization for sustainable growth

Industry leaders should prioritize actions that align scientific opportunity with operational viability and payer expectations. First, aligning clinical development with scalable manufacturing considerations from early-phase programs will reduce downstream delays and support faster transitions into commercial supply. Companies should consider modular and distributed manufacturing approaches as part of a hedged capacity strategy to reduce single-point failures in the supply chain. Second, investing in real-world evidence generation and health economics capabilities early will strengthen payer conversations and facilitate more predictable access pathways.

Third, leaders should actively pursue strategic partnerships to fill capability gaps-whether in viral vector production, cell therapy logistics, or regulatory intelligence-rather than attempting full vertical integration for every modality. Fourth, companies must develop differentiated channel strategies that reflect administration settings, from homecare to specialized oncology centers, ensuring that patient support, adherence programs, and reimbursement navigation are tailored to each channel. Finally, scenario planning that incorporates tariff volatility, geopolitical risks, and rapid technological shifts will enable more resilient capital allocation and portfolio decisions.

Methodological approach combining primary stakeholder engagement, authoritative secondary sources, and scenario analysis to ensure robust, actionable insights

This research synthesizes primary and secondary intelligence through a structured methodology designed to balance depth of insight with practical applicability. Primary inputs included structured interviews with clinical leaders, manufacturing experts, payers, and distribution partners, complemented by anonymized practitioner surveys to capture operational pain points and emergent practices. Secondary inputs drew on peer-reviewed literature, regulatory guidance, clinical trial registries, and company-published materials to validate trends and to map product archetypes against clinical and commercial pathways.

Analytical approaches combined qualitative thematic synthesis with scenario analysis to stress-test strategic implications under varied regulatory, tariff, and supply chain conditions. Cross-validation steps included expert review panels and iterative triangulation of findings across data sources to ensure robustness. The result is a reproducible framework that links modality characteristics, disease indication nuances, end-user requirements, and channel dynamics to actionable strategic recommendations.

Concluding synthesis tying together scientific potential, operational realities, and strategic actions required to translate innovation into sustained clinical and commercial success

In conclusion, cancer biologics are entering a phase where scientific possibility must be matched by operational rigor and strategic foresight. Breakthrough modalities such as cell and gene therapies and the continued evolution of monoclonal antibody formats create expansive therapeutic potential, but their successful translation into patient impact depends on integrated approaches to development, manufacturing, and commercialization. Organizations that proactively align cross-functional teams, invest in resilient supply chains, and cultivate payer-aligned evidence strategies will be best positioned to convert scientific advances into sustained clinical and commercial success.

Moving forward, leaders will need to treat strategic planning as a dynamic capability-one that iterates with new data, regulatory signals, and market feedback. By embracing modular manufacturing, targeted partnerships, and differentiated channel strategies, companies can navigate complexity while accelerating patient access to transformative biologics. The balance of innovation and operational excellence will determine which organizations convert opportunity into durable therapeutic impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Biologics Market, by Product Type

  • 8.1. Cancer Vaccines
  • 8.2. Cell Therapy
  • 8.3. Gene Therapy
  • 8.4. Monoclonal Antibodies
    • 8.4.1. Anti-CD20
      • 8.4.1.1. Obinutuzumab
      • 8.4.1.2. Rituximab
    • 8.4.2. Anti-HER2
      • 8.4.2.1. Pertuzumab
      • 8.4.2.2. Trastuzumab
    • 8.4.3. Anti-PD-1/PD-L1
      • 8.4.3.1. Atezolizumab
      • 8.4.3.2. Nivolumab
      • 8.4.3.3. Pembrolizumab
    • 8.4.4. Anti-VEGF
  • 8.5. Recombinant Proteins

9. Cancer Biologics Market, by Cancer Type

  • 9.1. Breast Cancer
  • 9.2. Colorectal Cancer
  • 9.3. Hematological Malignancies
  • 9.4. Lung Cancer
  • 9.5. Melanoma
  • 9.6. Prostate Cancer

10. Cancer Biologics Market, by End User

  • 10.1. Ambulatory Surgery Centers
  • 10.2. Homecare Settings
  • 10.3. Hospitals & Clinics
  • 10.4. Oncology Centers

11. Cancer Biologics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Cancer Biologics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cancer Biologics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cancer Biologics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Cancer Biologics Market

16. China Cancer Biologics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. ADC Therapeutics SA
  • 17.7. Agenus Inc.
  • 17.8. Amgen Inc.
  • 17.9. AstraZeneca PLC
  • 17.10. Autolus Therapeutics plc
  • 17.11. BeiGene, Ltd.
  • 17.12. Biocon Limited
  • 17.13. BioNTech SE
  • 17.14. Bristol-Myers Squibb Company
  • 17.15. F. Hoffmann-La Roche Ltd.
  • 17.16. GlaxoSmithKline plc
  • 17.17. Johnson & Johnson
  • 17.18. Merck & Co., Inc.
  • 17.19. Modex Therapeutics AG
  • 17.20. Novartis AG
  • 17.21. Pfizer Inc.
  • 17.22. Regeneron Pharmaceuticals, Inc.
  • 17.23. Sanofi S.A.
  • 17.24. Seagen Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CANCER BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CANCER BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY OBINUTUZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY OBINUTUZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY OBINUTUZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RITUXIMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RITUXIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PERTUZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PERTUZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PERTUZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY TRASTUZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY TRASTUZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY TRASTUZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ATEZOLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ATEZOLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ONCOLOGY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ONCOLOGY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. GCC CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GCC CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. GCC CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 183. GCC CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 184. GCC CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 185. GCC CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 186. GCC CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. GCC CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. G7 CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. G7 CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 210. G7 CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 211. G7 CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 212. G7 CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 213. G7 CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. G7 CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. G7 CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. NATO CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. NATO CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. NATO CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 219. NATO CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 220. NATO CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 221. NATO CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 222. NATO CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. NATO CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. NATO CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES CANCER BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA CANCER BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)